Company intelligence / Profile preview

Trans Chromosomics

Yonago, Tottori, Japan
Ownership
Private
Employees
~18
Development stage
Other
01

Overview

Trans Chromosomics is a Japanese biotechnology company and a spin-off from Tottori University that specializes in advanced chromosome engineering. The company leverages its proprietary Human Artificial Chromosome (HAC) and Mouse Artificial Chromosome (MAC) platforms to develop sophisticated drug discovery tools and therapeutic candidates. Its core offerings include the TC-mAb mouse, a fully humanized antibody-producing model, and the TC-huMDR1 mouse for evaluating the blood-brain barrier penetration of central nervous system drugs. Trans Chromosomics collaborates extensively with major pharmaceutical companies like Daiichi Sankyo and Eisai to accelerate the discovery of monoclonal antibodies and gene therapies for intractable conditions such as Duchenne muscular dystrophy. Additionally, the company provides specialized contract research services including high-precision karyotype and FISH analysis for regenerative medicine applications.

Therapeutic areas
OncologyNeurologyRare DiseasesInfectious Diseases
Modalities
Gene therapyMonoclonal antibodyCell therapyBiologicPeptidesInduced pluripotent stem cell derived therapy
Industry
Biotech
02

Drug pipeline

1 asset

1C008-DM1

Preclinical
03

Partnerships

Daiichi SankyoEisaiChiome BioscienceTakara BioWolves HandKan Research InstituteMedical & Biological Laboratories (MBL)

Beyond the preview

Go deeper on Trans Chromosomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans Chromosomics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call